Inventiva (NASDAQ:IVA) Coverage Initiated at UBS Group

Equities research analysts at UBS Group started coverage on shares of Inventiva (NASDAQ:IVA) in a report issued on Tuesday,Briefing.com Automated Import reports. The brokerage set a “neutral” rating and a $3.00 price target on the stock. UBS Group’s price target would indicate a potential upside of 11.11% from the stock’s current price.

Several other equities research analysts also recently commented on the company. HC Wainwright reduced their price objective on Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, October 15th. Stifel Nicolaus reduced their price target on shares of Inventiva from $25.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, September 26th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Inventiva Trading Down 2.5 %

NASDAQ IVA opened at $2.70 on Tuesday. Inventiva has a one year low of $1.53 and a one year high of $4.75. The stock has a 50-day moving average of $2.29 and a 200 day moving average of $2.68.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new position in shares of Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.